Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin Treatment in Obsessive-Compulsive Disorder
NCT03356483Phase 1Completed
- Sponsor
- Yale University
- Start
- Nov 2018
- Primary completion
- Jul 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of psilocybin in obsessive compulsive disorder (OCD) (2 arms), sponsored by Yale University. Primary endpoints: Yale-Brown Obsessive-Compulsive Scale at 12 weeks, Acute Yale-Brown Obsessive-Compulsive Scale at 48 hours and 2 more. Started Nov 2018; status: completed.
02
Drugs
psilocybin
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT03356483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03356483.